Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AtheroGenics, Inc.{AGIX}-nasdaq -- Ignore unavailable to you. Want to Upgrade?

To: mlrb2113 who wrote (286)	7/5/2007 11:12:12 PM
From: Clarksterh	Respond to of 332

Dr. Bob - I knew of the top line results, but had not seen the paper. Tx.

To: mlrb2113 who wrote (286)	7/6/2007 11:31:01 PM
From: Clarksterh	Read Replies (1) \| Respond to of 332

An interesting thing about the interim results for Avandia vs other diabetes drugs is that if Avandia increases MI/CV death risk, it does not appear to do it at anywhere near the 40 to 60% found by Nissen's meta-analysis. Note that while the above observation is undoubtedly not strictly stat sig (or even close) it is also true that such KM curves are virtually always substantially more stable than the worst case statistics implied by the computed p value.